September 12, 2017

  • A Johnson & Johnson pharmaceutical unit focused on the development of hepatitis C research said it will end its program amid a crowded market.

  • Janssen Sciences Ireland cited the increasing availability of a number of highly effective therapies addressing the medical need.

Getty Images

Shares of biotech company Achillion Pharmaceuticals were more...

Please reload

  • Black Facebook Icon
  • Black Twitter Icon
  • Black LinkedIn Icon
  • Black Google+ Icon